Frances S. Mair
John J. V. McMurray, Australian Catholic University
Lowrie, R., Mair, F. S, Greenlaw, N., Forsyth, P., McConnachie, A., Richardson, J., Khan, N., Morrison, D., Messow, C., Rae, B. & McMurray, JJ. (2011). The Heart failure and Optimal Outcomes from Pharmacy Study (HOOPS): Rationale, design, and baseline characteristics. European Journal of Heart Failure,13(8), 917-924. United Kingdom: Elsevier BV. Retrieved from https://doi.org/10.1093/eurjhf/hfr083
Aims: The effect on mortality and morbidity of pharmacist-led intervention to optimize pharmacological therapy in patients with systolic heart failure ( HF ) has not been tested in a large-scale, long-term, clinical trial. Methods: We describe the rationale and design of a UK, primary care-based, prospective cluster-randomized controlled trial of a pharmacist-led intervention in HF and report baseline characteristics of the patients randomized. Eighty-seven practices ( 1092 patients ) were assigned to the intervention arm and 87 practices ( 1077 patients ) to usual care. The average age of patients at baseline was 71 years, 70% were male, 86% were treated with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and 62% with a beta-blocker. Data for the primary outcome of death from any cause or hospitalization for HF will be available up to 31 December 2010, giving a mean follow-up of 5 years. More than 750 patients would have experienced the primary outcome during this period. The first secondary outcome is death from any cause or hospitalization for a cardiovascular reason. Deaths and hospitalizations are being identified using the Scottish National Health Service electronic patient record-linkage system ( hence the delay between the end of follow-up and database lock ). Conclusion: This trial is powered to provide a robust evaluation of the effect of pharmacist-led treatment optimization in patients with systolic HF in primary care.
Mary MacKillop Institute for Health Research